UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934


File	d by the R	legistrant ⊠	Filed by a Party other than the Registrant \Box		
Che	ck the app	propriate box:			
	Prelimina	ary Proxy Statement			
	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))				
	Definitive Proxy Statement				
X	Definitive	Definitive Additional Materials			
	Soliciting	g Material Pursuant t	o §240.14a-12		
		I	MAGENTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)		
			(Name of Person(s) Filing Proxy Statement, if other than the Registrant)		
Pay	ment of Fi	lling Fee (Check the	appropriate box):		
\boxtimes	No fee required.				
	Fee co	omputed on table bel	ow per Exchange Act Rules 14a-6(i)(1) and 0-11.		
	(1)	Title of each class	of securities to which transaction applies:		
	(2)	Aggregate number	of securities to which transaction applies:		
	(3)		her underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the ted and state how it was determined):		
	(4)	Proposed maximur	n aggregate value of transaction:		
	(5)	Total fee paid:			
	Fee paid previously with preliminary materials.				
			the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was the previous filing by registration statement number, or the Form or Schedule and the date of its filing.		
	(1)	Amount Previously	Paid:		
	(2)	Form, Schedule or	Registration Statement No.:		
	(3)	Filing Party:			

(4)	Date Filed:



Important Notice Regarding the Availability of Proxy Materials for the Magenta Therapeutics, Inc. 2020 Annual Meeting of Stockholders to be Held on June 5, 2020

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. To view the proxy statement and annual report, go to www.proxydocs.com/MGTA. To submit your proxy while visiting this site, you will need the 12 digit control number in the box below.





For a Convenient Way to VIEW Proxy Materials – and –



VOTE Online go to: www.proxydocs.com/MGTA

Proxy Materials Available to View or Receive:

- 1. Annual Report
- 2. Proxy Statement

Printed materials may be requested by one of the following methods:



INTERNET www.investorelections.com/MGTA



TELEPHONE (866) 648-8133

You must use the 12 digit control number located in the shaded gray box below.



*E-MAIL paper@investorelections.com

If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.

Notice of Magenta Therapeutics, Inc. 2020 Annual Meeting of Stockholders



Friday, June 5, 2020 9:00 a.m. Eastern Time

Annual Meeting to be held live via the Internet—please visit www.proxydocs.com/MGTA for virtual meeting registration details.

To be admitted to the Annual Meeting and vote your shares, you must register in advance at www.proxydocs.com/MGTA prior to the deadline of Wednesday, June 3, 2020 at 5:00 p.m. Eastern Time. The control number located in the shaded gray box will be required to register.

The Board of Directors recommends a vote FOR all the nominees listed in Proposal 1 and FOR Proposal 2.

- 1. To elect four class II directors to our Board of Directors, to serve until the 2023 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
 - 1. Jeffrey Albers
 - 2. Michael W. Bonney
 - 3. Anne McGeorge
 - 4. David T. Scadden, M.D.
- 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.